|Day Low/High||41.65 / 41.98|
|52 Wk Low/High||35.32 / 46.47|
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and...
Not intended for UK-based media
Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.
U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.
Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.
Sentiment's shifting, we're getting oversold and it looks like fear and panic are creeping in -- that's the way it should be.
Pfizer (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the...
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA ® (lorlatinib, available in the U.
The FDA approves Pfizer's treatment for a rare form of heart disease.
Pfizer Inc. (NYSE:PFE) announced today that the U.
Stocks ended mixed as the S&P 500 set a record close and the Nasdaq slumped on a revenue miss from Alphabet.
Pfizer posted stronger-than-expected first quarter earnings Tuesday, and boosted the mid-point of its full-year profit forecast thanks to anticipated gains in consumer healthcare.
We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.
Global stocks slipped lower for a second consecutive session Tuesday, pulling U.S. equity futures into the red, as investors reacted to renewed weakness in China's manufacturing sector and braced for the impact of softer-than-expected revenue gains from online ad giant Alphabet Inc.
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS (2).
U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.
Global stocks were mixed Monday as investors extended bets that surging economic growth, stronger-than-expected corporate earnings and a potentially dovish Federal Reserve will continue to push U.S. stocks to fresh record highs.
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP)...
The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
The board of directors of Pfizer Inc. today declared a 36-cent second-quarter 2019 dividend on the company's common stock, payable June 7, 2019 to shareholders of record at the close of business on May 10, 2019.
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.
Especially when healthcare CEOs discus political issues with analysts and reporters.
Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by...
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.